Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCH | P24723 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
| ▸ | CD209 | Q9NNX6 | 3/20 | 0.51 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186721 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8254322 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL18328428 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL1923753 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14217500 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL3924682 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL2300084 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL13851827 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL12030336 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5545675 | 1.00 | PRKD3 (0.56) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675654-A1 | IMPROVING THE TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2020-07-08 | — | — | EP | disclosed |
| EP-3664827-A1 | USE OF POLYPHENOL CONTAINING SUGAR CANE EXTRACTS FOR PREVENTING, IMPROVING OR TREATING A SKIN CONDITION | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2020-06-17 | — | — | EP | disclosed |
| US-20190167565-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS METHODS AND SYSTEMS | BEAUTY BIOLABS, LLC | 2019-06-06 | — | — | US | disclosed |
| US-10238597-B2 | Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2019040989-A1 | IMPROVING THE TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019028506-A1 | USE OF POLYPHENOL CONTAINING SUGAR CANE EXTRACTS FOR PREVENTING, IMPROVING OR TREATING A SKIN CONDITION | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2019-02-14 | — | — | WO | disclosed |
| US-20170143621-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS, LLC | 2017-05-25 | — | — | US | disclosed |
| US-20100319084-A1 | METABOLIC ENGINEERING FOR PLANT DISEASE RESISTANCE | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2010-12-16 | — | — | US | disclosed |
| EP-1733731-A1 | New uses of Glycerol derivatives in particular in cosmetics | AGRO INDUSTRIE RECHERCHES ET DEVELOPPEMENTS (A.R.D.) (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238597-B2 | Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems | CUTA, IL17A, TSLP | PRKD3 3627/4885PRKCG 4845/4885PRKCB 4758/4885 |
| US-20190167565-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS METHODS AND SYSTEMS | CUTA, IL17A, MMP11 | PRKD3 3544/4885PRKCG 4839/4885PRKCB 4724/4885 |
| US-20170143621-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS, METHODS AND SYSTEMS | CUTA, IL17A, TSLP | PRKD3 3627/4885PRKCG 4845/4885PRKCB 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.